heme-exposed intravenous immunoglobulin

Heme-exposed intravenous immunoglobulin is a modified formulation of standard intravenous immunoglobulin (IVIG) in which the immunoglobulin product is exposed to heme, an iron-containing porphyrin compound. IVIG is typically a pooled antibody product, predominately IgG, derived from human plasma, and used in the treatment of immunodeficiency disorders, autoimmune conditions, and some infections. IVIG works primarily through passive transfer of broadly reactive antibodies, anti-idiotype antibodies, and by modulation of the immune response, including inhibition of autoantibodies and inflammatory processes. Exposure to heme may modify the structure or activity of the immunoglobulins, potentially altering their immunomodulatory or inflammatory properties, but specific mechanisms or indications for "heme-exposed" IVIG are not established in the published literature. The term may refer to either a specific pre-clinical experimental formulation or a product investigated for altered immunogenic or pro-inflammatory activities. Mechanistic details for the "heme-exposed" preparation are not defined in clinical practice. Standard IVIG’s mechanisms of action include neutralization of antigens, modulation of Fc receptor function, inhibition of complement activation, and attenuation of autoantibody production[1][3][4].

Other names

heme-exposed intravenous immunoglobulin